Please assess the completion status of the following clinical trial:

Trial Title: UVA1 Light for Scleroderma and Similar Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 10-80 years~* Clinical diagnosis of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare, and other related conditions associated with altered dermal matrix.~* No disease states or physical conditions which would impair evaluation of the test site.~* Willing and able to receive UVA1 as directed in the protocol, make evaluation visits, and follow protocol restrictions.~* Signed, written, witnessed, informed consent form.~* Must live within driving distance of Ann Arbor, Michigan.~Exclusion Criteria:~* History of photosensitivity.~* Pregnant or nursing women.~* Systemic therapy for the fibrosing skin condition within 30 days prior to study enrollment.~* Involved in an investigational study within the previous 4 weeks.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- UVA1 Irradiation (Type: EXPERIMENTAL): UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.

Based on this trial design, predict the completion outcome and termination type (if applicable).